Amended and Restated Note issued to Arcion Therapeutics, Inc.



 Exhibit 10.97 
 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). NO SALE, PLEDGE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN
EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT. 
 THIS NOTE IS SUBJECT TO THE TERMS AND CONDITIONS OF THE PURCHASE AGREEMENT (AS DEFINED BELOW). 
 AMENDED AND RESTATED NOTE 
  

			
	$2,200,000.00	 	September 17, 2009

 For value received, Anesiva, Inc., a Delaware corporation (the
“Company”), promises to pay to the order of Arcion Therapeutics, Inc. (together with its successors and assigns, the “Holder”), the principal sum of Two Million Two Hundred Thousand Dollars ($2,200,000), together
with interest accrued but unpaid thereon, upon the terms of this Amended and Restated Note (this “Note”). 
 Interest shall accrue (a) on the original principal sum of Two Million Dollars ($2,000,0000.00) commencing on the date of the Closing until maturity and (b) on the additional principal sum of Two Hundred Thousand Dollars
($200,000.00) from the date hereof until maturity in each case at a continuously compounding rate equal to ten percent (10%) per annum payable in cash; provided, however, that, during the occurrence and continuance of an Event of
Default (as defined in that certain Secured Note Purchase Agreement, dated as of May 18, 2009, as amended by the First Amendment thereto, dated as of September 17, 2009 (as further amended, restated, supplemented, extended or otherwise
modified from time to time, the “Purchase Agreement”), among the Company and the Holder), interest shall accrue at a continuously compounding rate equal to fourteen percent (14%) per annum. All computations of interest shall be
made on the basis of a year of 365 or 366 days, as the case may be, for the actual number of days (including the first day but excluding the last) occurring in the period for which such interest is payable. 
 Unless earlier paid pursuant to the terms hereof or the Purchase Agreement or accelerated in connection with an Event of Default, subject to
the terms of the Purchase Agreement, the outstanding principal and accrued but unpaid interest shall be immediately due and payable on December 31, 2009 (the “Maturity Date”). Company may prepay this Note at any time without
penalty or premium. 
 1. This Note is issued pursuant to the terms of the Purchase Agreement. The Holder is entitled to the
benefit of, and is subject to certain restrictions contained in, the Purchase Agreement and the other Related Documents. Capitalized terms not otherwise defined herein








 
shall have the meanings ascribed to them in the Purchase Agreement. The indebtedness evidenced by this Note is secured by certain collateral, as more particularly described in that certain
Pledge, Security and Collateral Agent Agreement, dated as of May 18, 2009 (as may be further amended, restated, supplemented or modified from time to time, the “Security Agreement”), among the Company, AlgoRx Pharmaceuticals,
Inc. and the Collateral Agent and that certain Guaranty, dated as of January 20, 2009 (as may be further amended or modified from time to time, the “Guaranty”) by and between AlgoRx Pharmaceuticals, Inc. and the Holder. Each
holder of this Note will be deemed, by its acceptance hereof, to have agreed to the provisions and to have made the representations and warranties set forth in Section 4 the Purchase Agreement. Subject to the terms of the Purchase Agreement,
this Note is transferable by surrender hereof at the principal office of the Company, duly endorsed or accompanied by a written instrument of transfer duly executed by the registered holder of this Note or by any other method permitted by the
Purchase Agreement. 
 2. All payments hereunder shall be applied in the order provided for in the Purchase Agreement. Whenever
any payment hereunder shall be stated to be due, or whenever any return payment date or any other date specified hereunder would otherwise occur, on a day other than a Business Day, then such payment shall be made, and such return payment date or
other date shall occur, on the next succeeding Business Day, and such extension of time shall in such case be included in the computation of payment of interest hereunder. 
 3. All payments in respect of this Note shall be in immediately available lawful money of the United States of America and shall be sent so
as to be received no later than 2 p.m. (Pacific time) on the date of payment, at the address specified in the Purchase Agreement, or at such other address as may be specified from time to time by such Holder in a written notice delivered to the
Company. All payments in respect of this Note shall be made unconditionally in full without any deduction, set off, counterclaim or other defense. If any scheduled payment date is not a Business Day, such payment shall be made on the next succeeding
Business Day. 
 4. The Company hereby waives demand, notice, presentment, protest and notice of dishonor. 
 5. (a) The terms of this Note shall be construed in accordance with the laws of the State of California, as applied to contracts entered
into by California residents within the State of California, which contracts are to be performed entirely within the State of California. The Company hereby (i) submits to the exclusive jurisdiction of the courts of the County of San Francisco,
State of California and the Federal courts of the United States sitting in the Northern District of the State of California for the purpose of any action or proceeding arising out of or relating to this Note, the Purchase Agreement and the Related
Documents; (ii) agrees that all claims in respect of any such action or proceeding may be heard and determined in such courts; (iii) irrevocably waives (to the extent permitted by applicable law) any objection that it now or hereafter may
have to the laying of venue of any such action or proceeding brought in any of the foregoing courts, and any objection on the ground that any such action or proceeding in any such court has been brought in an inconvenient forum; and (iv) agrees
that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner permitted by law. 







 (b) The parties agree that any dispute, controversy or claim (including any counterclaim)
(each, a “Dispute”) arising out of or relating to this Note, the Purchase Agreement or any Related Documents shall be finally resolved by confidential binding arbitration in San Francisco County, California as the sole and exclusive
method of resolving such dispute, controversy or claim. Any Dispute shall be settled by arbitration under the rules then in effect of JAMS/Endispute conducted by a single arbitrator reasonably acceptable to the parties. The arbitrator shall have no
power to amend this Note, the Purchase Agreement or any Related Documents. The arbitrator shall issue an award in writing (including an explanation of the grounds for such award) as promptly as practicable that shall be final and binding on the
parties. Judgment upon any award thus obtained may be entered in any court having jurisdiction thereof. No action at law or in equity based upon any claim arising out of or related to this Note, the Purchase Agreement or any Related Documents shall
be instituted in any court by any party except (a) an action to compel arbitration pursuant to this Section 5(b); or (b) an action to enforce an award obtained in an arbitration proceeding in accordance with this Section 5(b).
Pending the submission to arbitration and thereafter until the arbitrator publishes its award, each party shall, except in the event of termination, continue to perform all its obligations under this Note, the Purchase Agreement and the Related
Documents without prejudice to a final adjustment in accordance with the award. 
 6. Notwithstanding any provision of this Note
to the contrary, any payments hereunder deemed to be interest shall not exceed the maximum rate permitted by applicable law. To the extent that any interest otherwise paid or payable by the Company to the Holder shall have been finally adjudicated
to exceed the maximum amount permitted by applicable law, such interest shall be retroactively deemed to have been a required repayment of principal (and any such amount paid in excess of the outstanding principal amount shall be promptly returned
to the Company). 
 7. Any term of this Note and the other Securities may be amended and the observance of any term of this Note
and the other Securities may be waived (either generally or in a particular instance and either retroactively or prospectively), only in accordance with the terms of the Purchase Agreement. Any such amendment or waiver shall be effective only for
the specific instance and for the specific purpose for which given. 
 8. No remedy herein conferred upon the Holder is intended
to be exclusive of any other remedy, and each and every such remedy shall be cumulative and shall be in addition to every right or other remedy now or hereafter existing at law or in equity or by statute or otherwise. 
 9. No course of dealing between the Company and the Holder or any delay on the part of the Holder in exercising any rights or remedies shall
operate as a waiver of any such right or remedy of the Holder. 
 10. This Note shall be binding on and inure to the benefit of
and be enforceable by the Company, the Holder and their respective successors and assigns. The Company may not assign, transfer, hypothecate or otherwise convey its rights, benefits, obligations or duties hereunder without the prior express written
consent of the Majority Investors. Any such purported assignment, transfer, hypothecation or other conveyance by the Company without the prior express written consent of the Majority Investors shall be void. 







 11. Whenever possible, each provision of this Note shall be interpreted in such manner as to
be effective and valid under all applicable laws and regulations. If, however, any provision of this Note shall be prohibited by or invalid under any such law or regulation in any jurisdiction, it shall, as to such jurisdiction, be deemed modified
to conform to the minimum requirements of such law or regulation, or, if for any reason it is not deemed so modified, it shall be ineffective and invalid only to the extent of such prohibition or invalidity without affecting the remaining provisions
of this Note, or the validity or effectiveness of such provision in any other jurisdiction. 
 12. This Note is issued pursuant
to the Purchase Agreement and in connection with the Security Agreement, the Pledge Agreement and the other Related Documents. Material terms applicable to this Note are set forth in the Purchase Agreement, the Security Agreement, the Pledge
Agreement and the other Related Documents. This Note shall be interpreted in a manner to give full effect to its provisions and the provisions of the Purchase Agreement, the Security Agreement, the Pledge Agreement and the other Related Documents.

 13. The Company agrees to pay on demand all costs and expenses of the Holder, and the reasonable fees and disbursements of
its counsel (including the allocated costs of internal counsel), in connection with: (i) any amendments, modifications or waivers of the terms hereof or of the Purchase Agreement or of any other Related Documents; (ii) the protection or
preservation of the Holder’s rights under this Note, under the Purchase Agreement or under any other Related Documents, whether by judicial proceeding or otherwise; (iii) enforcement or attempted enforcement of, and preservation of any
rights under, this Note, the Purchase Agreement or any other Related Documents; (iv) creating, maintaining and perfecting Liens in favor of the Collateral Agent, for the benefit of the Holder, including filing and recording fees and expenses,
and (v) any out-of-court workout or other refinancing or restructuring or in any bankruptcy case, including, without limitation, any and all losses, costs and expenses sustained by the Holder as a result of any failure by the Company to perform
or observe its obligations contained herein or in the Purchase Agreement or in any of the other Related Documents. 
 [Remainder
of page intentionally left blank] 







 This Note has been issued in reliance upon the representations and warranties and covenants
and agreements of the Company and the Holder set forth in the Purchase Agreement. 
  

			
	ANESIVA, INC.
		
	 By:
	 	 /s/ John Tran

		
	 Name:
	 	 John Tran

		
	 Title:
	 	 VP, Finance & CAO



 Accepted and Agreed: 
  

			
	ARCION THERAPEUTICS, INC.
		
	 By:
	 	 /s/ James N. Campbell

		
	 Name:
	 	 James N. Campbell

		
	 Title:
	 	 CEO


 [SIGNATURE PAGE TO NOTE]